Enhancing Prostate Cancer Care Through Tandem PSMA- and GRPR-targeted Radionuclide Treatment (EANM 2026) - Sep 29, 2026 - Abstract #OP-085; Pres time: Oct 18, 2026; 09:45 AM - 11:15 AM; Location: Hall E2; "Secondly, the binding affinity, uptake, retention, and therapeutic effect of [161Tb]Tb-NeoB vs. [177Lu]Lu-NeoB was determined in PCa cell line PC-3 (GRPR+/PSMA-) and PCa tissues to select the best radionuclide for GRPR-TRT... The first steps towards a tandem PSMA/GRPR-TRT strategy, i.e. (1) simultaneous detection of terbium-161 and lutetium-177 labelled radiopharmaceuticals for future patient selection and dosimetry, (2) selection of suitable radionuclides for TRT, and (3) assessing the biological effect of co-incubation on uptake, were successfully taken. Next, efficacy studies in homo- and heterotypic spheroids, the latter representing target heterogeneity, will be performed to determine the best treatment schedule for tandem PSMA-/GRPR-TRT."
Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • GRP-10
|
|
L. Bokhout 1; C. M. Ntihabose 1, 2; G. J. L. H. van Leenders 3; C. H. M. van Deurzen 3; E. H. de Blois 1; S. U. Dalm 1
|